1. Scrip
  2. >>Therapy Areas

Novartis Targets Chronic Urticaria As Ligelizumab Enters Late-Stage Trials

 
• By John Davis

Two Phase III studies, PEARL 1 and PEARL 2, will compare Novartis's candidate anti-IgE antibody with the previous generation anti-IgE MAb, Xolair, for the treatment of chronic spontaneous urticaria.  

Urticaria
Intense itching is a feature of urticaria • Source: Shutterstock

With data from a positive Phase II study in hand, Novartis AG says it will now compare its investigational anti-IgE antibody, ligelizumab (QGE031) with its marketed anti-IgE MAb, Xolair (omalizumab), in two head-to-head Phase III studies, PEARL 1 and PEARL 2, that it is initiating in patients with chronic spontaneous urticaria (CSU).

Novartis is considered to be a leader in immune-dermatology with recently launched products such as the anti-IL-17A, Cosentyx (secukinumab), making an impact in the marketplace. Sales of more mature products like the 2003-launched blockbuster-selling Xolair (marketed in collaboration with Genentech Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.